Summary of change in the 2.2012 version of the Guidelines for Basal cell and squanmous cell shin cancers from the 1.2012 version include:
BCC-3
Primary treatment of high-risk basal cell shin cancer pathway: After the "Primary Treatment" and "Adjuvant Treatment" pathways, a new recommendation was added that states, "if residual disease is present, and surgery and RT are contraindicated, consider mutidisciplinary tumor board consulation + therapy".